This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ford, C. D.
Right arrow Articles by Burke, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ford, C. D.
Right arrow Articles by Burke, J. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1998, p. 1402-1405, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Oral Antimicrobial Prophylaxis in Bone Marrow Transplant Recipients: Randomized Trial of Ciprofloxacin versus Ciprofloxacin-Vancomycin

Clyde D. Ford,* William Reilly, John Wood, David C. Classen, and John P. Burke

Department of Medicine, LDS Hospital, Salt Lake City, Utah 84143

Received 24 November 1997/Returned for modification 25 February 1998/Accepted 16 March 1998

The optimal oral antimicrobial prophylactic regimen for bone marrow transplant recipients remains to be elucidated. We randomized 84 patients to receive either oral ciprofloxacin or ciprofloxacin plus vancomycin at hospital admission. Patients were monitored for bacteremias and clinical parameters, and stool and throat swab surveillance cultures were performed. The addition of vancomycin resulted in a significant decrease in the frequency of patients with surveillance cultures positive for coagulase-negative staphylococci (stool cultures, 44 versus 23%; throat swab cultures, 37 versus 19%) and alpha-hemolytic streptococci (throat swab cultures, 90 versus 60%). The frequencies of positivity for Candida spp. and gram-negative organisms on surveillance cultures were comparable. Despite these results, no differences in the incidences of bacteremias (12 of 41 versus 12 of 43 patients) or clinical parameters such as number of days to first fever, total number of febrile days, length of stay, and number of transfusions could be demonstrated. Because of a lack of efficacy of vancomycin and emerging problems with vancomycin-resistant isolates, vancomycin should not be used in oral antimicrobial prophylaxis regimens.


* Corresponding author. Mailing address: Department of Medicine, LDS Hospital, 8th Ave. and C St., Salt Lake City, UT 84143. Phone: (801) 321-2232. Fax: (801) 321-2214. E-mail: ldcford{at}ihc.com.


Antimicrobial Agents and Chemotherapy, June 1998, p. 1402-1405, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Gafter-Gvili, A., Paul, M., Fraser, A., Leibovici, L. (2007). Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 59: 5-22 [Abstract] [Full Text]  
  • Gafter-Gvili, A., Fraser, A., Paul, M., Leibovici, L. (2005). Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients. ANN INTERN MED 142: 979-995 [Abstract] [Full Text]  
  • Cruciani, M., Malena, M., Bosco, O., Nardi, S., Serpelloni, G., Mengoli, C. (2003). Reappraisal With Meta-Analysis of the Addition of Gram-Positive Prophylaxis to Fluoroquinolone in Neutropenic Patients. JCO 21: 4127-4137 [Abstract] [Full Text]